ENLIVEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.7 USD | -1.45% |
|
+3.63% | +56.79% |
| 06-11 | Baird Initiates Enliven Therapeutics With Outperform Rating, $32 Price Target | MT |
| 05-29 | Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Bio Therapeutic Drugs | -1.45% | +3.63% | +56.79% | +11.80% | - | 1.02B |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ELVN Stock
- Charts Enliven Therapeutics, Inc.
- Comparison Chart